1. Taetle R, Aickin M, Yang LM, Panda L, Emerson J, Roe D, Adair L, Thompson F, Liu Y, Wisner L,Davis JR, Trent J, Alberts DS. Chromosome abnormalities in ovarian adenocarcinoma: I. Nonrandom chromosome abnormalities from 244 cases. Genes Chromosomes Cancer 1999; 25(3): 290-300.
2. Deger RB, Faruqi ShA, Noumoff JS. Karyotypic analysis of 32 malignant epithelial ovarian tumors. Cancer Genet Cytogenet 1997; 96(2): 166-173.
3. Thompson FH, Taetle R, Trent JM, Liu Y, Massey-Brown K, Scott KM, Weinstein RS, Emerson JC, Alberts DS, Nelson MA. Band 1p36 abnormalities and t(1;17) in ovarian carcinoma. Cancer Genet Cytogenet 1997; 96(2): 106-110.
4. Couturier J. Uterus: endometrial carcinoma. Atlas Genet Cytogenet Oncol Haematol (Elecronic journal) 1999 (http://www.infobiogen.fr/services/chromcancer/Tumors/endometrID5045.html)
5. Wang JCh, Masson AMM, Tonin PN, Provencher, Eydoux P. Trisomy of chromosome 10 in two cases of ovarian carcinoma. Cancer Genet Cytogenet 2000; 118(1): 65-68.
6. Thompson FH. Cytogenetic methods and findings in human solid tumors. In: Barch MJ, Knutsen T, Spur beck J, eds. The ACT Cytogenetics Laboratory Manual, 3rd ed. Philadelphia: Lippincott Raven. 1997; 98-118.
7. Musio A, Mariani T, Vezzoni P, Frattini A. Heterogeneous gene distribution reflects human genome complexity as detected at the cytogenetic level. Cancer Genet Cytogenet 2002; 134(2): 168-171.
8. Musio A, Zambroni D, Vessoni P, Mariani T. Chromosomes, genes and cancer breakpoints. Cancer Genet Cytogenet 2002; 139(2): 141-142.
9. Mandahl N. Methods in solid tumour cytogenetics. In: Rooney DE, Czepulkowski BH, eds. Human Cyto genetics: A Practical Approach, 2nd ed. Oxford:IRL Press at Oxford University Press. 1992; 155-187.
10. Köhler A. Chromosome staining. In: Wegner RD, ed. Diagnostic Cytogenetics. Berlin: Springer Verlag. 1999; 56-60.
11. ISCN 1995: an international system for human cytogenetic nomenclature (1995): recommendations of the International Standing Committee for Human Cytogenetic Nomenclature, Memphis, TN, USA, October 9-13, 1994. In: Mitelman F, ed. Basel: Karger.1995.
12. 13. Imamura T, Arima T, Kato H, Miyamoto S, Sasazuki T, Wake N. Chromosomal deletions and Kras gene mutations in human endometrial carcinomas.Int J Cancer 1992; 51(1): 47-52.
13. Argüden YT, Hac2hanefio.lu S. Kanser sitogeneti .i. Klinik Gelisim 2000; 13(8-9-10): 330-335 (in Turkish).
14. Dasgupta S, Chakraborty SB, Roy A, Roychowdhury S, Panda CK. Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients. J Clin Pathol Mol Pathol 2003; 56(5): 263-269.
15. Rao PH, Mathew S, Kelsen DP, Chaganti RSK. Cytogenetics of gastric and esophageal adenocarcinomas. Cancer Genet Cytogenet 1995; 81(2): 139-143.
16. Bodmer D, Janssen I, Jonkers Y, Berg E, Dijkhuizen T, Debiec-Rychter M, Schoenmakers E, Kessel AG. Molecular cytogenetic analysis of clustered sporadic and familial renal cell carcinoma-associated 3q13~q22 breakpoints. Cancer Genet Cytogenet 2002;136(2): 95-100.
17. Guenet L, Henry C, Toutain B, Dubourg C, Le Gall JY, David V, Le Treut A. Eucaryotic translation termination factor gene (ETF1/eRF1) maps at D5S500 in a commonly deleted region of chromosome 5q31 in malignant myeloid diseases. Cytogenet Cell Genet 2000; 88(1-2): 82-86.
18. Gisselsson D, Andreasson P, Meis-Kindblom JM, Kindblom LG, Mertens F, Mandahl N. Amplification of 12q13 and 12q15 sequences in a sclerosing epitheloid fibrosarcoma. Cancer Genet Cytogenet 1998;107(2): 102-106.
19. Stock AD, Dennis TR. A translocation breakpoint at chromosome band 12q13 associated with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 1999; 111(2): 166-168.
20. Santulli B, Kazmierczak B, Napolitano R, Caliendo I, Chiappetta G, Rippe V, Bullerdiek J, Fusco A. A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia. Cancer Genet Cytogenet 2000; 119(1): 70-73.
21. Yeh YA, Rao PH, Cigna CT; Middlesworth W, Lefkowitch JH, Murty VVVS. Trisomy 1q, 2 and 20 in a case of hepatoblastoma: possible significance of 2q35-q37 and 1q12-q21 rearrangements. Cancer Genet Cytogenet 2000; 123(2): 140-143.
22. Gabra H, Watson JEV, Taylor KJ, Mackay J, Leonard RCF, Steel CM, Porteous DJ, Smyth JF. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res 1996;56(5): 950-954.
23. Abeysinghe HR, Cao Q, Xu J, Pollock S, Veyberman Y, Guckert NL, Keng P, Wang N. THY1 expression is associated with tumor suppression of human ovarian cancer. Cancer Genet Cytogenet 2003;143(2): 125-132.
24. Forrest DL, Lee CL. Constitutional rearrangements of 7q22 in hematologic malignancies: a new case report. Cancer Genet Cytogenet 2002; 139(1):75-77.
